CONMED Corporation 2017 Form 10-K Summary
Business context and reporting period
CONMED is a medical technology company providing surgical devices and equipment for minimally invasive procedures in orthopedic and general surgery. Products are sold worldwide through direct sales, subsidiaries, and distributors in more than 100 countries. The filing covers the fiscal year ended December 31, 2017; quarterly information indicates fourth-quarter results, but this is an annual filing rather than a standalone Q4 filing.
- Approximately 3,100 employees.
- 2017 sales mix: 54% orthopedic surgery and 46% general surgery.
- Approximately 80% of revenue came from single-use products and approximately 48% of sales were to customers outside the United States.
- General surgery growth continued to benefit from the AirSeal product acquired through the 2016 SurgiQuest acquisition.
Financial performance and key metrics
| Metric | 2017 | 2016 | Change |
|---|---|---|---|
| Net sales | $796.4 million | $763.5 million | 4.3% increase |
| Gross profit | $431.0 million | $408.3 million | 5.6% increase |
| Gross margin | 54.1% | 53.5% | 60 basis-point increase |
| Income from operations | $46.9 million | $37.7 million | 24.6% increase |
| Operating margin | 5.9% | 4.9% | 100 basis-point increase |
| Net income | $55.5 million | $14.7 million | Significant increase |
| Diluted EPS | $1.97 | $0.52 | Significant increase |
| Cash flow from operations | $65.6 million | $39.9 million | Increase |
| Capital expenditures | $12.8 million | $14.8 million | Decrease |
- Orthopedic surgery revenue increased 1.6% to $428.9 million, reversing the 2016 decline.
- General surgery revenue increased 7.6% to $367.5 million, led by AirSeal and new advanced surgical and endoscopic products.
- Interest expense increased to $18.2 million from $15.4 million; the weighted-average borrowing rate increased to 3.52% from 2.93%.
- The reported 2017 effective tax rate was negative 93.1%, primarily because of a $31.9 million deferred tax benefit from the Tax Cuts and Jobs Act. Reported net income and EPS therefore benefited materially from a nonrecurring or unusual tax item.
- Cash and cash equivalents were $32.6 million at year-end, including approximately $26.6 million held by foreign subsidiaries.
- Total debt was approximately $486.4 million at December 31, 2017, including $327.0 million drawn on the revolving facility and approximately $157.5 million under the term loan. Available revolving capacity was approximately $194.9 million, subject to approximately $3.1 million of letters of credit.
- Net working capital was $206.8 million and shareholders’ equity was $631.4 million.
- The quarterly data show fourth-quarter 2017 net sales of $222.6 million and net income of $46.7 million, compared with $204.1 million and $6.7 million, respectively, in fourth-quarter 2016. The fourth quarter included the $31.9 million tax benefit.
Material changes versus the prior comparable period
- Sales growth improved from 2016, with both product lines contributing; general surgery remained the faster-growing business.
- Gross margin improved mainly because of lower restructuring costs.
- Operating income improved despite $17.5 million of legal expenses and litigation-related costs in selling and administrative expense, including the $12.2 million Lexion verdict accrual and related legal costs.
- Cash flow from operations increased by $25.7 million, while investing cash usage declined sharply because 2016 included the $256.5 million cash payment for SurgiQuest.
- Debt declined modestly from approximately $498.5 million at year-end 2016, but interest expense remained elevated relative to pre-SurgiQuest periods.
- Restructuring charges declined: $2.9 million in cost of sales and $1.3 million in selling and administrative expense in 2017, compared with $7.6 million and $6.7 million, respectively, in 2016.
- International currency movements had a limited net effect on sales but reduced 2017 income before taxes by approximately $0.9 million compared with 2016.
Outlook, commentary, risks, contingencies, and unusual items
- Management stated that operating cash flow, cash on hand, and available borrowing capacity should be adequate for working capital, debt service, capital expenditures, and share repurchases in the foreseeable future.
- 2018 capital expenditures were expected to be between $15 million and $20 million.
- The company expects the Tax Cuts and Jobs Act to reduce the tax rate on domestic earnings, but its 2017 tax accounting was provisional and subject to further refinement.
- The Lexion litigation resulted in a $12.2 million verdict accrual. Post-verdict motions remained pending, and the company was evaluating an appeal. Additional disgorgement, corrective advertising, and attorneys’ fees were possible.
- EndoDynamix sellers sought approximately $12.7 million in accelerated contingent and royalty payments. CONMED disputed the claim and expected to defend the litigation.
- The senior credit agreement matures in January 2021 and contains financial covenants and restrictions on debt, dividends, acquisitions, asset sales, and other activities. The company reported compliance at year-end.
- A 1% increase in average market interest rates was estimated to increase annual interest expense by approximately $4.9 million, assuming no repayments.
- Key risks include healthcare spending and purchasing cycles, competitive pricing, regulatory approvals and inspections, product recalls and liability, raw-material and supplier availability, foreign exchange, cybersecurity, intellectual property litigation, acquisition integration, allograft tissue supply, and debt covenant constraints.
- The company adopted or planned to adopt several accounting standards, including the new revenue recognition standard effective January 1, 2018. Approximately $8.2 million of 2017 group purchasing organization fees were expected to be reclassified from selling and administrative expense to a reduction of revenue, with no material expected impact on net income or EPS.
- Management and the independent auditor concluded that internal control over financial reporting was effective as of December 31, 2017.
Most important facts for investors to verify
- Separate the $31.9 million Tax Cuts and Jobs Act benefit from recurring earnings when assessing 2017 profitability and EPS.
- Review the Lexion post-verdict proceedings and the EndoDynamix contingent-payment litigation for potential additional cash exposure.
- Reconcile reported debt, scheduled 2021 maturities, revolving availability, interest-rate sensitivity, and credit agreement covenants.
- Assess whether general surgery growth, particularly AirSeal, can offset moderate orthopedic growth and support margin expansion.
- Evaluate the effect of the 2018 revenue-recognition presentation change on reported revenue and historical comparability.
- Monitor foreign exchange exposure, forward-contract losses expected to be recognized in 2018 and 2019, and the substantial international sales concentration.